MX2021007504A - Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos. - Google Patents

Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos.

Info

Publication number
MX2021007504A
MX2021007504A MX2021007504A MX2021007504A MX2021007504A MX 2021007504 A MX2021007504 A MX 2021007504A MX 2021007504 A MX2021007504 A MX 2021007504A MX 2021007504 A MX2021007504 A MX 2021007504A MX 2021007504 A MX2021007504 A MX 2021007504A
Authority
MX
Mexico
Prior art keywords
sup
amide
beta
alpha
hydroxy
Prior art date
Application number
MX2021007504A
Other languages
English (en)
Spanish (es)
Inventor
Francesco G Salituro
Maria Jesus Blanco-Pillado
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2021007504A publication Critical patent/MX2021007504A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2021007504A 2018-12-21 2019-12-20 Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos. MX2021007504A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862784229P 2018-12-21 2018-12-21
US201862784222P 2018-12-21 2018-12-21
PCT/US2019/067953 WO2020132504A1 (en) 2018-12-21 2019-12-20 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof

Publications (1)

Publication Number Publication Date
MX2021007504A true MX2021007504A (es) 2021-10-13

Family

ID=69591712

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021007504A MX2021007504A (es) 2018-12-21 2019-12-20 Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos.
MX2025000126A MX2025000126A (es) 2018-12-21 2021-06-18 Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025000126A MX2025000126A (es) 2018-12-21 2021-06-18 Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos

Country Status (12)

Country Link
US (1) US20220372067A1 (cg-RX-API-DMAC7.html)
EP (1) EP3898646B1 (cg-RX-API-DMAC7.html)
JP (2) JP7692830B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210107050A (cg-RX-API-DMAC7.html)
CN (1) CN113195512A (cg-RX-API-DMAC7.html)
AU (2) AU2019403415B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012242A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124371A1 (cg-RX-API-DMAC7.html)
IL (1) IL284183A (cg-RX-API-DMAC7.html)
MX (2) MX2021007504A (cg-RX-API-DMAC7.html)
TW (2) TWI848034B (cg-RX-API-DMAC7.html)
WO (1) WO2020132504A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
IL312610B2 (en) 2018-12-05 2026-05-01 Sage Therapeutics Llc Neuroactive steroids and methods of using them
TWI848034B (zh) * 2018-12-21 2024-07-11 美商賽吉醫療公司 神經活性類固醇及其組合物
CN115768781A (zh) * 2020-06-24 2023-03-07 萨奇治疗股份有限公司 3.α.-羟基,17.β.-C(O)-N-芳基取代的神经活性类固醇及其组合物
CN119192275B (zh) * 2024-08-22 2025-05-30 湖南玉新药业有限公司 一种3-羰基-4-氮杂-5α-雄甾-17β-羧酸化合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP4717314A2 (en) 2011-10-14 2026-04-01 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
US9512170B2 (en) * 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
MY190408A (en) * 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
DK3258939T3 (da) * 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
WO2018013613A1 (en) * 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
IL312610B2 (en) * 2018-12-05 2026-05-01 Sage Therapeutics Llc Neuroactive steroids and methods of using them
TWI848034B (zh) * 2018-12-21 2024-07-11 美商賽吉醫療公司 神經活性類固醇及其組合物

Also Published As

Publication number Publication date
TW202438080A (zh) 2024-10-01
JP7858720B2 (ja) 2026-05-14
TWI892697B (zh) 2025-08-01
TWI848034B (zh) 2024-07-11
JP2022514385A (ja) 2022-02-10
CA3124371A1 (en) 2020-06-25
JP7692830B2 (ja) 2025-06-16
EP3898646A1 (en) 2021-10-27
AU2025267433A1 (en) 2025-12-04
WO2020132504A1 (en) 2020-06-25
AU2019403415A1 (en) 2021-07-08
BR112021012242A2 (pt) 2021-09-28
CN113195512A (zh) 2021-07-30
AU2019403415B2 (en) 2025-08-21
KR20210107050A (ko) 2021-08-31
TW202038967A (zh) 2020-11-01
US20220372067A1 (en) 2022-11-24
EP3898646B1 (en) 2026-02-18
JP2024107296A (ja) 2024-08-08
MX2025000126A (es) 2025-02-10
IL284183A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
MX2025000126A (es) Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos
MX2024009540A (es) Esteroides neuroactivos y composiciones de estos.
MX2024004788A (es) Esteroides neuroactivos y sus metodos de uso.
MX2024008999A (es) Esteroides neuroactivos y composiciones de estos.
MX2024014845A (es) Esteroides neuroactivos no saturados 9(11) y sus metodos de uso
MX2024011494A (es) Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para su uso en el tratamiento de trastornos del snc.
EP4442695A3 (en) 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
EP4360707A3 (en) Compositions for treating spinal muscular atrophy
MX2025008327A (es) Composiciones y metodos para el tratamiento de trastornos del snc
EP4484440A3 (en) Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
EP4252848A3 (en) Oxysterols and methods of use thereof
WO2019035914A8 (en) Macrocyclic mcl-1 inhibitors and methods of use
MX2022006470A (es) Tiromimeticos novedosos.
MX2021007247A (es) Derivados de rapamicina.
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
ZA202203107B (en) Azaindole carboxamide compounds for the treatment of mycobacterial infections
MX388175B (es) Compuestos terapéuticos y métodos para utilizarlos
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MX2019014321A (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.